Health
FDA revokes EUA for monoclonal antibody therapy bamlanivimab to treat patients with COVID-19 – News-Medical.Net
Today, the U.S. Food and Drug Administration revoked the emergency use authorization (EUA) that allowed for the investigational monoclonal antibody therapy bamlanivimab,…
Today, the U.S. Food and Drug Administration revoked the emergency use authorization (EUA) that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and certain pediatric patients. Based on its ongoing analysis of emerging scientific data, specifically the sustained increase of SARS-CoV-2 viral variants that are resistant to bamlanivimab alone resulting in the increased risk for treatment…
-
General11 hours agoByford rail extension opening marks final stage of Perth Metronet
-
Noosa News16 hours agoFatal traffic crash, Baringa – Sunshine Coast
-
General22 hours agoBritish and US planes fly 12-hour mission to patrol Russian border
-
General12 hours agoMango the muster cat draws attention to western Queensland’s ongoing recovery